Translate Bio (TBIO) Prices 9M Share Common Offering at $10/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Celestica (CLS) Tops Q3 EPS by 31c, Offers Guidance
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- CAE agrees to sell Flightscape unit to SITA for $500 million
Translate Bio Announces Pricing of Public Offering of Common Stock
September 17, 2019 9:07 PM EDTLEXINGTON, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the pricing of its underwritten public offering of 9,000,000 shares of its common stock at a public offering price of $10.00 per share, for aggregate gross proceeds of $90 million, before deducting underwriting discounts and commissions and offering expenses payable by Translate Bio. In addition, Translate Bio has granted the underwriters a 30-day option to purchase up to... More



